{
    "id": 27027,
    "fullName": "MYD88 M232T",
    "impact": "missense",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "MYD88 M232T lies within the TIR domain of the Myd88 protein (PMID: 27102345). M232T results in high activity of NF-kappaB compared to MYD88 wild-type in vitro and therefore, is predicted to result in a gain of function (PMID: 21179087).",
            "references": [
                {
                    "id": 2809,
                    "pubMedId": 21179087,
                    "title": "Oncogenically active MYD88 mutations in human lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21179087"
                },
                {
                    "id": 10043,
                    "pubMedId": 27102345,
                    "title": "Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27102345"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4615,
        "geneSymbol": "MYD88",
        "terms": [
            "MYD88",
            "MYD88D"
        ]
    },
    "variant": "M232T",
    "createDate": "10/03/2017",
    "updateDate": "10/04/2017",
    "referenceTranscriptCoordinates": {
        "id": 152158,
        "transcript": "NM_002468",
        "gDna": "chr3:g.38140768T>C",
        "cDna": "c.695T>C",
        "protein": "p.M232T",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 12110,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with primary central nervous system lymphoma harboring CARD11 S622del, CD79B Y196C, MYD88 M232T, and TNFAIP3 del demonstrated a partial response when treated with Imbruvica (ibrutinib) (PMID: 28619981).",
            "molecularProfile": {
                "id": 28415,
                "profileName": "CARD11 S622del CD79B Y196C MYD88 M232T TNFAIP3 del"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 3234,
                "name": "central nervous system lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10035,
                    "pubMedId": 28619981,
                    "title": "Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28619981"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28406,
            "profileName": "MYD88 M232T",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28415,
            "profileName": "CARD11 S622del CD79B Y196C MYD88 M232T TNFAIP3 del",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 152159,
            "transcript": "XM_005265172",
            "gDna": "chr3:g.38140787T>C",
            "cDna": "c.695T>C",
            "protein": "p.M232T",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 152158,
            "transcript": "NM_002468",
            "gDna": "chr3:g.38140768T>C",
            "cDna": "c.695T>C",
            "protein": "p.M232T",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}